An experimental drug called enlicitide reduced levels of low-density lipoprotein (LDL), or “bad” cholesterol by almost 60% in ...

Alzheimer's disease (AD) currently afflicts over 6 million Americans with expected financial burdens for long-term care and hospices for this population exceeding 350 billion. These numbers threaten ...

Studies by researchers at Washington University School of Medicine in St. Louis have found that high levels of a normal protein that is associated with reduced heart disease also protects against ...

Pharmaceutical company Merck has created a new pill called enlicitide, which promises to lower "bad" cholesterol as ...

Evinacumab reduced LDL cholesterol by 50% over placebo in high-risk patients with severe hypercholesterolemia whose condition was resistant to standard treatments, according to findings reported at ...

A new oral PCSK9 inhibitor, enlicitide, offers a daily pill option for lowering LDL-C, a key cardiovascular disease risk ...

Background: Cardiovascular disease caused by atherosclerosis is responsible for 18 million deaths annually, highlighting a significant need for new medical therapies, especially for patients who are ...

The drug enlicitide reduced cholesterol for adults with high levels due to an inherited disorder and may also work for a broader population.

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is highly expressed in adult hepatocytes. PCSK9 binds to and promotes the degradation of the low-density lipoprotein (LDL) receptor, thereby ...

Researchers have uncovered a long-sought link in the battle to control cholesterol and heart disease. The protein that interferes with low-density lipoprotein (LDL) receptors that clear 'bad' ...